Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Met-Rx, AST To Place Warnings On "Andro" Products Under FTC Settlement

This article was originally published in The Tan Sheet

Executive Summary

Sports supplement marketers Met-Rx USA and AST Sports Science agree in individual settlements with the Federal Trade Commission to place warnings on their androstenedione ("andro") supplements as well as an additional warning on andro supplements also containing ephedra.

You may also be interested in...



Prop 65 Andro Settlements Include “Corrective Advertising” Provision

Settling defendants in California's Prop 65 litigation against androstenedione supplement marketers would pay from $1,341 to $4,546 each to fund "corrective advertising" programs, according to proposed consent judgments filed in Oakland state court

Prop 65 Andro Settlements Include “Corrective Advertising” Provision

Settling defendants in California's Prop 65 litigation against androstenedione supplement marketers would pay from $1,341 to $4,546 each to fund "corrective advertising" programs, according to proposed consent judgments filed in Oakland state court

Prop 65 Andro Settlements Include “Corrective Advertising” Provision

Settling defendants in California's Prop 65 litigation against androstenedione supplement marketers would pay from $1,341 to $4,546 each to fund "corrective advertising" programs, according to proposed consent judgments filed in Oakland state court

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS090588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel